← ANALYST RATINGS · TIPRANKS
Biogen (BIIB): analyst forecast and price target
Analyst consensus
Moderate Buy17 Buy6 Hold1 Sell
Ratings of 24 analysts in the last 3 months12-month forecast
Based on 24 price targets given in the last 3 months, the average target is $242, the highest $300, the lowest $175. The average is +4.0% from the last price of $233.
Analyst ratings 43
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $223 → $259+16.1% | Buy | +11.3% | Upgrade | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $236 → $271+14.8% | Buy | +16.5% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $224 → $257+14.7% | Hold | +10.5% | Downgrade | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $210 → $240+14.3% | Hold | +3.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $231 → $264+14.3% | Buy | +13.5% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $233 → $268+15.0% | Buy | +15.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $250 | Buy | +7.5% | Reiterated | 15.10.26on TipRanks 07:40 | +0.8%next day 0.0% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $208 → $220+5.8% | Hold | −5.4% | Reiterated | 12.10.26on TipRanks 08:45 | +1.7%next day −0.2% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $215 | Hold | −7.6% | Reiterated | 12.10.26on TipRanks 07:35 | +1.7%next day −0.2% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $245 | Buy | +5.3% | Reiterated | 12.10.26on TipRanks 06:55 | +1.7%next day −0.2% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $210 → $300+42.9% | Buy | +28.9% | Upgrade | 12.10.26on TipRanks 05:10 | +1.7%next day −0.2% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $240 → $270+12.5% | Buy | +16.1% | Assigned | 09.10.26on TipRanks 08:40 | +2.7%next day +1.7% · 5 days +5.0% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $260 → $256−1.5% | Buy | +10.0% | Reiterated | 08.10.26on TipRanks 08:50 | −1.3%next day +2.7% · 5 days +8.0% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $256 | Buy | +10.0% | Reiterated | 06.10.26on TipRanks 07:35 | −0.9%next day −0.1% · 5 days +2.8% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $255 | Buy | +9.6% | Reiterated | 05.10.26on TipRanks 09:55 | +1.0%next day −0.9% · 5 days +2.2% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $245 | Buy | +5.3% | Reiterated | 05.10.26on TipRanks 07:56 | +1.0%next day −0.9% · 5 days +2.2% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $256 | Buy | +10.0% | Reiterated | 02.10.26on TipRanks 12:35 | −2.1%next day +1.0% · 5 days +1.5% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $255 | Buy | +9.6% | Reiterated | 01.10.26on TipRanks 10:25 | −1.5%next day −2.1% · 5 days −3.3% | ↗ |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $236 | Buy | +1.4% | Reiterated | 25.09.26on TipRanks 13:21 | 0.0%next day +1.2% · 5 days −3.2% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $250 | Buy | +7.5% | Reiterated | 18.09.26on TipRanks 06:50 | −1.7%next day +0.1% · 5 days +4.3% | ↗ |
| Morten Herholdt★★★★★★★★★★#4305 · hits 69% · avg +8.7% | HSBC | $165 → $175+6.1% | Sell | −24.8% | Reiterated | 10.09.26on TipRanks 06:30 | +2.8%next day −0.1% · 5 days +1.1% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | — | Hold | — | Reiterated | 09.09.26on TipRanks 06:21 | −0.4%next day +2.8% · 5 days +3.6% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $225 → $245+8.9% | Buy | +5.3% | Reiterated | 03.09.26on TipRanks 06:50 | −0.2%next day −1.3% · 5 days −2.1% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $240 → $260+8.3% | Buy | +11.8% | Assigned | 25.08.26on TipRanks 06:35 | +0.9%next day +0.1% · 5 days −1.6% | ↗ |
| Alexandria Hammond★★★★★★★★★★#7870 · hits 50% · avg +0.6% | Wolfe Research | $300 | Buy | +28.9% | Upgrade | 13.08.26on TipRanks 11:40 | +0.2%next day −0.2% · 5 days +3.7% | ↗ |
| Emily Field★★★★★★★★★★#5009 · hits 45% · avg +1.9% | Barclays | $200 | Hold | −14.0% | Reiterated | 12.08.26on TipRanks Aug 13 04:25 | +2.2%next day +0.2% · 5 days +6.5% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $221 → $241+9.0% | Buy | +3.6% | Reiterated | 03.08.26on TipRanks 11:30 | −2.0%next day +1.5% · 5 days +0.6% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $200 → $215+7.5% | Hold | −7.6% | Reiterated | 03.08.26on TipRanks 06:45 | −2.0%next day +1.5% · 5 days +0.6% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $214 → $242+13.1% | Buy | +4.0% | Reiterated | 02.08.26on TipRanks 12:51 | −2.0%next day +1.5% · 5 days +0.6% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $235 | Buy | +1.0% | Reiterated | 31.07.26on TipRanks Jul 30 09:45 | −2.3%next day −3.1% · 5 days −4.4% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $215 | Hold | −7.6% | Reiterated | 31.07.26on TipRanks Jul 29 10:43 | +3.3%next day −2.3% · 5 days −6.8% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $185 → $210+13.5% | Hold | −9.7% | Reiterated | 30.07.26on TipRanks Jul 31 08:18 | −2.3%next day −3.1% · 5 days −4.4% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $255 | Buy | +9.6% | Reiterated | 30.07.26on TipRanks 10:49 | −2.3%next day −3.1% · 5 days −4.4% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $237 → $251+5.9% | Buy | +7.9% | Reiterated | 30.07.26on TipRanks 10:49 | −2.3%next day −3.1% · 5 days −4.4% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $225 → $240+6.7% | Buy | +3.2% | Reiterated | 30.07.26on TipRanks 09:15 | −2.3%next day −3.1% · 5 days −4.4% | ↗ |
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $245 → $248+1.2% | Buy | +6.6% | Reiterated | 30.07.26on TipRanks 07:10 | −2.3%next day −3.1% · 5 days −4.4% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | $215 → $225+4.7% | Buy | −3.3% | Assigned | 30.07.26on TipRanks Jul 29 19:10 | −2.3%next day −3.1% · 5 days −4.4% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $222 → $231+4.1% | Hold | −0.7% | Reiterated | 30.07.26on TipRanks Jul 29 12:03 | +3.3%next day −2.3% · 5 days −6.8% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $226 | Buy | −2.9% | Upgrade | 29.07.26on TipRanks 14:24 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $221 → $236+6.8% | Buy | +1.4% | Reiterated | 29.07.26on TipRanks 14:24 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $228 → $234+2.6% | Buy | +0.6% | Reiterated | 29.07.26on TipRanks 14:24 | — | |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $256 | Buy | +10.0% | Reiterated | 29.07.26on TipRanks 11:43 | +3.3%next day −2.3% · 5 days −6.8% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 29.07.26on TipRanks 11:26 | +3.3%next day −2.3% · 5 days −6.8% | ↗ |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $225 → $231+2.7% | Buy | −0.7% | Reiterated | 29.07.26on TipRanks 10:43 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $204 → $212+3.9% | Hold | −8.9% | Reiterated | 29.07.26on TipRanks 10:43 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $222 → $226+1.8% | Buy | −2.9% | Reiterated | 29.07.26on TipRanks 10:43 | — | |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $215 → $219+1.9% | Hold | −5.9% | Reiterated | 29.07.26on TipRanks 08:20 | +3.3%next day −2.3% · 5 days −6.8% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $260 → $280+7.7% | Buy | +20.4% | Assigned | 21.07.26on TipRanks Jul 24 05:14 | +0.8%next day −2.6% · 5 days +2.2% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $250 | Buy | +7.5% | Reiterated | 13.07.26on TipRanks Jul 14 08:55 | +5.7%next day −8.5% · 5 days −3.4% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | — | Hold | — | Reiterated | 13.07.26on TipRanks Jul 14 06:50 | +5.7%next day −8.5% · 5 days −3.4% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | — | Hold | — | Reiterated | 10.07.26on TipRanks Jul 14 09:50 | −0.3%next day +5.7% · 5 days +5.0% | ↗ |
| Eric Schmidt FCA★★★★★★★★★★#358 · hits 51% · avg +84.1% | Cantor Fitzgerald | $206 | Buy | −11.5% | Initiated | 22.06.26on TipRanks 08:55 | +1.9%next day +0.2% · 5 days +8.9% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Initiated | 15.05.26on TipRanks 21:20 | −0.5%next day 0.0% · 5 days −1.0% | ↗ |
| Ilya Zubkov★★★★★★★★★★#5009 · hits 59% · avg +9.5% | Freedom Capital Markets | $185 → $245+32.4% | Buy | +5.3% | Upgrade | 01.05.26on TipRanks 10:15 | −1.4%next day +0.4% · 5 days +1.1% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $255 → $250−2.0% | Buy | +7.5% | Reiterated | 31.10.25on TipRanks 09:45 | +2.8%next day −2.0% · 5 days +2.4% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Biogen
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $238 at a price of $226 (+5.5%); now: $242 at $233 (+4.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 39 | 41 | 54 | 40 | 36 | 17 |
| Hold | 39 | 32 | 34 | 23 | 22 | 6 |
| Sell | 1 | 0 | 1 | 1 | 2 | 1 |
Earnings and sales forecast
Next report: 28.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.00 (from $1.44 to $2.67). Last quarter: $3.60.
Sales
Next quarter’s sales estimate — $2.6B (from $2.5B to $2.8B). Last quarter: $2.6B.
Best top-analyst consensus in the sector · Healthcare
About Biogen
- CEO: Christopher A. Viehbacher
- Employees: 7,500
- 225 Binney Street, Cambridge, MA, 02142, US
- www.biogen.com
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neu
Data from the stock’s TipRanks forecast page, read 23 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗